$PLPL -study shows benefits to Breast Cancer Patients: Could Benefit From Plandai Phytofare(TM) Citrus Products
BALTIMORE, MD--(Marketwired - Sep 17, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that with October (The Breast Cancer Awareness Month) around the corner, it is interesting to note that Plandaí Biotechnology, Inc.'s (OTCQB: PLPL) Phytofare™ Citrus Products may prove to be useful in the fight against breast cancer due to the high bioavailability of its citrus bioflavonoid product.
For example, many breast cancer patients who undergo surgery to treat breast cancer suffer from a common side effect known as Lymphedema. This condition is marked by intense swelling of the arm due to damage done to the lymph nodes in the surgical procedure. An older study from about 15 years ago demonstrated significantly less swelling in patients who took a bioflavonoid supplement in a double blind study of 57 women. (Pecking AP, Fevrier B, Wargon C, et al. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). Angiology 1997; 48:93-98)
Bioflavonoids are naturally occurring compounds extracted from plants and rich in antioxidants and are found in fruits like lemons that contain vitamins A & C and a variety of minerals including potassium and pectin. These bioflavonoids help protect the nutrients from oxidation in the body. To that end, Plandaí is set to release the Phytofare™ Catechin Complex in the coming months and the citrus-based Limonoid Glycoside Complex products in 2014. The Phytofare™ citrus bioflavonoid product will be 7 to 12 times more effective from a blood absorption perspective than any other bioflavonoid supplement on the market today. Using dietary supplements similar to this has been shown effective in treating all sorts or ailments and sicknesses like Lymphedema in the past.
Fast forward to today where many organizations like BreastCancer.org are recommending dietary supplements and general diets that include citrus bioflavonoids to aid in fighting the effects of Lymphedema. Unfortunately, Lymphedema will continue to be a common problem as breast cancer remains a huge issue in women's health and bioflavonoids in generally have very poor bioavailability -- often around 5% absorption. That can dramatically change due to the high bioavailability associated with its citrus bioflavonoid product.
Breast cancer remains at the forefront of women's health concerns. According to American Cancer Society an estimated 1 in 8 women will be diagnosed with breast cancer in their lifetime and over 235,000 women expected to be diagnosed per year in and approximately 40,000 will die from the disease.
Breast cancer surgery remains a very popular treatment in fighting the disease. Lymphedema occurs as a side effect of this surgery in some cases but also occurs in a larger cross section of society in general. The Plandaí Phytofare™ Citrus product will aid symptoms of this ailment and provide better results than competitors because of its superior bioavailability, or absorption in the blood, as mentioned above. This market is yet another that should help Plandaí generate revenue as the Company ramps up production by year-end 2013 and into 2014.
Goldman Small Cap Research sponsored articles, reports, and updates on Plandai as well as associated disclaimers and disclosures can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented pending Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Contact:
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com
